Millions of Americans used Zantac (ranitidine) for years to treat heartburn and acid reflux. In 2020, the FDA requested the withdrawal of all ranitidine products from the U.S. market after testing revealed the drug could produce dangerously high levels of a cancer-causing chemical called NDMA. Since then, consumers who developed cancer after taking Zantac have been filing lawsuits against the drug’s manufacturers.
Contact Counsel Hound for a free case evaluation to find out if you qualify for a Zantac lawsuit. There are no fees unless you win.
This guide covers the history of the Zantac recall, the cancer risks linked to ranitidine, the current status of the litigation, and what consumers need to know about filing a claim.
What Happened With Zantac?
Zantac (generic name: ranitidine) was one of the most widely used over-the-counter and prescription medications in the United States. It was first approved by the FDA in 1983 and became available without a prescription in 1996. At its peak, Zantac was used by millions of people daily to manage heartburn, gastroesophageal reflux disease (GERD), and stomach ulcers.
In September 2019, the independent pharmacy Valisure discovered that ranitidine could form N-Nitrosodimethylamine (NDMA), a probable human carcinogen, at levels far exceeding the FDA’s acceptable daily intake. Valisure’s testing found that ranitidine could generate over 3 million nanograms of NDMA per tablet when heated, compared to the FDA’s acceptable limit of 96 nanograms per day.
The problem was not contamination during manufacturing. Instead, the ranitidine molecule itself was unstable and could break down into NDMA under normal storage conditions, including exposure to temperatures above room temperature. This meant that the drug could become more dangerous the longer it sat on store shelves or in medicine cabinets.
On April 1, 2020, the FDA requested that all manufacturers withdraw ranitidine products from the U.S. market. The agency concluded that NDMA levels in ranitidine increase over time and under higher-than-room-temperature storage conditions, making the drug unsafe for continued use.
What Is NDMA and Why Is It Dangerous?
NDMA (N-Nitrosodimethylamine) is classified as a probable human carcinogen by the International Agency for Research on Cancer (IARC) and the EPA. It is a chemical compound that can damage DNA and trigger the growth of cancer cells.
NDMA is found in small amounts in some foods, water, and industrial processes. The concern with Zantac was that the levels of NDMA generated by the drug far exceeded what the body encounters through normal environmental exposure, and users were ingesting it daily for months or years.
Cancers that have been linked to NDMA exposure in medical studies and in the Zantac litigation include:
- Bladder cancer
- Stomach cancer
- Liver cancer
- Esophageal cancer
- Pancreatic cancer
- Colorectal cancer
- Kidney cancer
- Intestinal cancer
- Prostate cancer
- Breast cancer
The risk appears to increase with the duration and frequency of use. Consumers who took Zantac daily for years face higher potential exposure to NDMA than those who used it occasionally.
Current Status of the Zantac Litigation
The Zantac litigation has followed a complex path through both federal and state courts.
Federal MDL
Thousands of Zantac lawsuits were consolidated into a multidistrict litigation (MDL No. 2924) in the Southern District of Florida. In December 2022, the federal MDL judge excluded the plaintiffs’ expert witnesses, ruling that they could not reliably prove that Zantac caused the plaintiffs’ specific cancers. This decision effectively dismissed the federal cases.
However, this ruling applied only to the federal MDL. It did not affect cases filed in state courts, which operate under different evidentiary standards.
State Court Cases
After the federal setback, the Zantac litigation shifted to state courts, particularly in Delaware, California, and Illinois. State courts apply different rules for expert testimony and scientific evidence, and some have allowed Zantac cases to move forward.
Several states have scheduled or completed bellwether trials to test the evidence and guide settlement discussions. The outcomes of these trials are being closely watched by both sides and will significantly influence the future of the litigation.
Manufacturers Involved
The Zantac lawsuits name multiple manufacturers and distributors as defendants, including:
- Sanofi (maker of brand-name Zantac)
- GlaxoSmithKline (original developer of ranitidine)
- Boehringer Ingelheim (former manufacturer)
- Pfizer (former distributor)
- Various generic ranitidine manufacturers
What Did the Manufacturers Know?
A central issue in the Zantac litigation is what manufacturers knew about the NDMA risk and when they knew it. Documents uncovered during the litigation suggest that some companies were aware of potential problems with ranitidine’s stability long before the 2019 discovery by Valisure.
Plaintiffs argue that manufacturers had scientific data suggesting ranitidine could form NDMA under conditions that real-world users would commonly encounter, including storing the medication in a warm bathroom or car. Despite this knowledge, the companies continued to market Zantac aggressively, earning billions in annual revenue from the drug.
The failure-to-warn allegations are strengthened by the fact that Zantac was available over the counter without a prescription. OTC consumers received no warnings about potential cancer risks and had no doctor intermediary reviewing the latest safety data on their behalf. For an OTC medication taken by millions of people daily, the duty to warn consumers directly was especially important.
If evidence demonstrates that manufacturers prioritized profits over consumer safety, courts may award punitive damages in addition to compensatory damages. Punitive damages are designed to punish the wrongdoer and discourage similar behavior by other companies.
Who Can File a Zantac Lawsuit?
You may qualify to file a Zantac lawsuit if you meet these criteria:
- You used Zantac (ranitidine) regularly for a sustained period (typically several months or more)
- You have been diagnosed with one of the cancers linked to NDMA exposure
- Your cancer diagnosis occurred during or after your use of ranitidine
Both prescription and over-the-counter Zantac users may qualify. You do not need to have used brand-name Zantac specifically; generic ranitidine products carry the same NDMA risk.
Some factors that strengthen a Zantac claim include long-term daily use (one year or more), a cancer diagnosis that is among the types most closely associated with NDMA exposure, and the availability of pharmacy or prescription records documenting your purchase history. Even if you do not have perfect records, an attorney can help you reconstruct your usage history through pharmacy databases and medical records.
Family members of someone who died from cancer potentially linked to Zantac use may also file a wrongful death claim.
Request a free consultation with Counsel Hound to discuss whether your cancer diagnosis may be connected to Zantac use.
What Compensation Is Available?
Zantac lawsuit plaintiffs seek compensation for:
- Medical expenses: Cancer treatment costs including surgery, chemotherapy, radiation, immunotherapy, and palliative care
- Future medical costs: Ongoing monitoring, follow-up treatments, and any long-term care needs
- Lost wages: Income lost during cancer treatment and recovery
- Lost earning capacity: Reduced ability to work due to the cancer or its treatment effects
- Pain and suffering: Physical pain from the cancer and its treatment
- Emotional distress: Anxiety, depression, and the psychological impact of a cancer diagnosis
- Loss of enjoyment of life: Impact on daily activities, relationships, and quality of life
- Punitive damages: If evidence shows manufacturers knew about the NDMA risk and failed to act
Settlement amounts in pharmaceutical litigation vary widely based on the type and severity of cancer, the duration of drug use, the age of the plaintiff, and the strength of the evidence linking the drug to the diagnosis. For details on how settlements are taxed, see our guide on personal injury settlement taxes.
Alternative Medications After the Recall
Since the removal of ranitidine from the market, doctors have recommended several alternative medications for heartburn and acid reflux. If you were previously taking Zantac, your healthcare provider may have switched you to:
- Famotidine (Pepcid): Another H2 blocker that works similarly to ranitidine but has not shown the same NDMA contamination issues
- Proton pump inhibitors (PPIs): Medications like omeprazole (Prilosec), esomeprazole (Nexium), and lansoprazole (Prevacid) that reduce stomach acid through a different mechanism
- Antacids: Over-the-counter products like Tums and Maalox for occasional heartburn relief
Switching to an alternative medication does not affect your right to file a lawsuit over past Zantac use. The legal claim is based on the harm caused by the ranitidine you already consumed, regardless of what medication you use now.
Steps to Take If You Used Zantac
If you used Zantac or generic ranitidine and have been diagnosed with cancer, or if you are concerned about your health after past use, here is what to do:
- Stop taking ranitidine: All ranitidine products have been withdrawn from the market. If you still have any in your medicine cabinet, dispose of them following FDA guidelines. Do not flush them or throw them in the trash.
- Talk to your doctor: Discuss your history of ranitidine use and any symptoms you may be experiencing. Ask about screening for cancers associated with NDMA exposure, especially if you used the drug for an extended period.
- Document your usage: Gather any records of your Zantac use, including pharmacy records, prescription history, and receipts. Many pharmacies retain purchase records that can help establish how long and how frequently you used the drug.
- Keep medical records: If you have been diagnosed with cancer, collect all medical records including pathology reports, treatment records, and doctor’s notes about the diagnosis.
- Consult an attorney: A personal injury attorney experienced in pharmaceutical litigation can evaluate whether your cancer diagnosis may be connected to Zantac use and guide you through the legal process.
Time is important. Statutes of limitations apply to Zantac claims, and filing deadlines vary by state. Most attorneys offer free consultations and work on a contingency fee basis, so there is no cost to explore your options.
Contact Counsel Hound today for a free case evaluation. We connect consumers affected by Zantac with vetted, experienced attorneys who handle pharmaceutical lawsuits on a no-fee-unless-you-win basis.
Frequently Asked Questions About Zantac Lawsuits
Can I still file a Zantac lawsuit after the federal MDL dismissal?
Yes. The federal MDL ruling did not end all Zantac litigation. Cases continue to move forward in state courts across the country. State courts apply different evidentiary standards, and several have allowed Zantac cases to proceed. An attorney can advise you on where and how to file your claim.
What if I used generic ranitidine instead of brand-name Zantac?
The NDMA issue was caused by the ranitidine molecule itself, not by how a specific brand manufactured the drug. Generic ranitidine carries the same risk as brand-name Zantac. Users of generic versions may file claims against the generic manufacturers as well as the companies that originally developed and marketed ranitidine.
How long do I have to file a Zantac lawsuit?
The statute of limitations varies by state, typically ranging from one to four years. The clock usually starts from the date of your cancer diagnosis or when you first learned (or should have learned) about the connection between ranitidine and cancer. Because these deadlines are strict, consulting an attorney promptly protects your rights.
What evidence do I need for a Zantac claim?
Key evidence includes pharmacy records showing your ranitidine purchases, prescription records, medical records documenting your cancer diagnosis, and pathology reports. Your attorney can help you gather these records and work with medical experts to establish the connection between your drug use and your diagnosis.
Is there a Zantac settlement yet?
As of 2026, there is no global settlement covering all Zantac cases. Individual settlements and verdicts have occurred in state courts, and the litigation is ongoing. The outcomes of bellwether trials in state courts are expected to influence future settlement discussions. Your attorney will keep you updated on developments that affect your case.
